CURRENT RESEARCH TOPICS IN PHARMACY:

Microbiology Debates

December 14th, 2022 14.00 PM ISTANBUL

FOR REGISTRATION:



First Session- Moderator: Büşra ERTAŞ 14.00-15.45 PM

Welcome- Assoc.Prof.Esra TATAR

Bacteriotheraphy – Dr. Zahraa AMER HASHIM

Mosul University, Mosul, Iraq

Antibiotic resistance – Assist.Prof. Pervin RAYAMAN

Marmara University, Istanbul, Turkey

The vaccination in Albania: An assessment of the level of knowledge and behaviour of the population regarding vaccines.- Assoc.Prof. *Mirela MIRAÇI*University of Medicine, Tirana, Albania

Chicken contamination with thermotolerant Campylobacter in Tunisia: Antibiotic resistance and virulence profiling –Dr.Awatef BEJAOUI Institut Pasteur de Tunis, Tunis, Tunisia

Second Session- Moderator: Esra TATAR 16.00-17.45 PM

Plant phenolics and their synthetic derivatives as inhibitors of *Helicobacter pylori*: Suggestion for a new mechanism of action - *Assoc.Prof.* Simone CARRADORI

"G. d'Annunzio" University of Chieti-Pescara *University, Chieti Italy*

Pomegranate rind extract with Zn (II) combination as a new therapeutic agent for oral care products- Dr.Vildan ÇELİKSOY Cardiff University, Cardiff, UK

The antimicrobial effects of honey and other bee-derived products- Dr.Saira KHAN Cardiff University, Cardiff, UK

Chair

Prof. Hatice Kübra ELÇİOĞLU

Vice Chairs

Prof. Levent KABASAKAL & Assoc. Prof. Esra TATAR

ORGANIZING & SCIENTIFIC COMMITTEE

Editorial Board of Journal of Research in Pharmacy <u>https://www.irespharm.com/</u>

 \mathbb{R}^{p}

Journal of Research in Pharmacy

ONLINE SYMPOSIUM

An international open-access journal of pharmacy and pharmaceutical sciences

Formerly published as Marmara Pharmaceutical Journa

CURRENT RESEARCH TOPICS IN PHARMACY:

Microbiology Debates

December 14th, 2022 14.00 PM ISTANBUL

ORGANIZING & SCIENTIFIC COMMITTEE

Editorial Board of Journal of Research in Pharmacy https://www.jrespharm.com/

Esra Tatar (Vice Chair of Organizing Committee) Marmara University, Istanbul, Turkey

Levent Kabasakal (Vice Chair of Organizing Committee Marmara University, Istanbul, Turkey

Ayşe Nur Hazar Yavuz (Secretary) Marmara University, Istanbul, Turkey

Abdikarim Mohammed Abdi Yeditepe University, Istanbul, Turkey

Afife Büsra Uğur Kaplan

Ahmet Emir Ege University, Izmir, Turkey

Ali Demir Sezer Marmara University, Istanbul, Turkey

Ammad Ahmad Faroogi Institute of Biomedical and Genetic Engineering (IBGE), Islamabad, Pakistan

Ana V. Pejčić University of Kragujevac, Kragujevac, Serbia

Anisa Elhamili University of Tripoli, Tripoli, Libya

Annalisa Chiavaroli G. d'Annunzio University of Chieti-Pescara, Chieti, Italy

Antoaneta Trendafilova Bulgarian Academy of Sciences, Sofia, Bulgaria

Ayfer Beceren Marmara University, Istanbul, Turkey

Ayşe Esra Karadağ Istanbul Medipol University, Istanbul, Turkey

Ayşenur Günaydın Akyıldız Bezmialem Vakıf University, Istanbul, Turkey

Bahadır Bülbül

Düzce University, Düzce, Turkey

Betul Okuyan Marmara University, Istanbul, Turkey

Büşra Ertaş Marmara University, Istanbul, Turkey

Ceren Emir Ege University, Izmir, Turkey

Claudio Ferrante
G. d'Annunzio University of Chieti-Pescara, Chieti, Italy

Derya Özsavcı Marmara University, Istanbul, Turkey

Dinesh Kumar Indian Institute of Technology (BHU), Varanasi, India

Ebru Altuntaş Istanbul University, Istanbul, Turkey

Enkelejda Goci Aldent University, Tirana, Albania

Erkan Rayaman Marmara University, Istanbul, Turkey

Gizem Tatar Yılmaz Karadeniz Technical University, Trabzon, Turkey

Gülberk Uçar Hacettepe University, Ankara, Turkey

Gülgün Tınaz Marmara University, İstanl rsity, Istanbul, Turkey

Gülsah Gedik

Hamide Sena Özbay Hacettepe University, Ankara, Turkey

Hasan Erdinç Sellitepe Technical University, Trabzon, Turkey

İ. İrem Tatlı Çankaya Hacettepe University, Ankara, Turkey

Kerem Buran University of Health Sciences, Istanbul, Turkey

Klodiola Dhamo Aldent University, Tirana, Albania

Lejla KlepoUniversity of Sarajevo, Sarajevo, Bosnia and Herzegovina

Lokman Ayaz Trakya University, Edirne, Turkey

Lorena Memushaj Aldent University, Tirana, Albania

Maja Ortner Hadžiabdić University of Zagreb, Zagreb, Croatia

Merve Kabasakal University of Health Sciences, Istanbul, Turkey

Mesut Sancar

Marmara University, Istanbul, Turkey

Mirela Miraçi University of Medicine, Tirana, Albania

Mohd Younis Rather Government Medical College Srinagar, Srinagar, India

Murat Doğan Cumhuriyet University, Sivas, Turkey

Nurdan Tekin
University of Health Sciences, Istanbul, Turkey

Nurettin Yaylı Karadeniz Technical University, Trabzon, Turkey

Ongun Mehmet Saka Ankara University, Ankara, Turkey

Oya Kerimoğlu Marmara University, İstanbul, Turkey

University of Valencia, Burjassot, Spain

Pinar Talay Pinar

Rezarta Shkreli Aldent University, Tirana, Albania

Rümeysa Keleş Kaya Sakarya University, Sakarya, Turkey

Saeideh Soltani

Isfahan University of Medical Sciences, Isfahan, Iran

Sakine Tuncay Tanrıverdi Ege University, Izmir, Turkey

Simone Carradori G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy

Somaieh Soltani Tabriz University of Medical Sciences, Tabriz, Iran

Tarik CatićSarajevo School of Science and Technology, Sarajevo, Bosnia and

Turgut Taşkın Marmara University, Istanbul, Turkey

Uğur Karagöz Trakya University, Edirne, Turkey

Ünzile Yaman Katip Çelebi University, İzmir, Turkey

Viktorija Maksimova Goce Delcev University, Stip, Republic of N. Macedonia

Vildan Çeliksoy Cardiff University, Cardiff, UK

Yeliz Şahin Marmara University, Istanbul, Turkey

Zahraa Amer Hashim Mosul University, Mosul, Iraq

Zeina Althanoon

Zoran Zekovıć University of Novi Sad, Novi Sad, Serbia



Journal of Research in Pharmacy

BACTERIOTHERAPY

Zahraa Amer HASHIM



Department of Microbiology and Immunology, College of Pharmacy, Mosul University, Mosul, Iraq hashimz@uomosul.edu.iq

Humans are in symbiosis with the microbiota in the gastrointestinal tract, with over 100 trillion microbiota, including 1000 types and 1 million associated genes. Genetic analysis have shown that failure of the human-enteric symbiosis ecosystem, the so-called dysbiosis, is closely related to growing disease groups, including inflammatory bowel disease (IBD) in developed countries [1]. The change in daily habit and lifestyle have been the major contributing factors. This lifestyle refers to the inappropriate use of antibiotics, higher rate of cesarean section, artificial milk, improved hygiene, highfat and low-fiber diet, and stress, which all can cause dysbiosis [2]. Bacteriotherapy is a treatment that prophylactically and therapeutically corrects the composition of disturbed intestinal microbiota using "good bacteria" and is a promising recent development that has been proved to be effective in managing a number of infectious diseases, cancer and psychotic and nervous disorders [3].

The worldwide emergence of bacterial resistance to antibacterial agents has produced a need for new methods of combating bacterial infections. This need is forced on us by the long time lag in developing new antibacterial agents. Even though new agents may be in the pipeline, they will not solve all current resistance problems. In addition, we also have to recognise that the use of antibacterial agents not only targets resistant bacteria but also disturbs normal human flora, which may itself further inhibit our defence against infection. Bacteriotherapy, as an alternative, has been shown effective in preventing and treating certain infections of bacterial, viral and fungal origin. Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit. Borody and colleagues used FMT to treat 6 patients with refractory ulcerative colitis and follow up at 1-13 years post-FMT showed no clinical evidence of ulcerative colitis [4]. Similarly, Duplessis et al. utilized FMT to treat a patient with severe Crohn's disease complicated by refractory CDI [5]. Obesity is another condition that could potentially benefit from FMT. FMT from lean to obese individuals led to increased insulin sensitivity in the patients compared to the control group [6].

Gut microbiome is becoming more important in the realm of cancer immunotherapy. Waves of clinical trials have been initiated to examine the clinical outcomes of modulating gut microbiota in the context of cancer therapy [7].

However, it remains challenging for bacteriotherapy to be adopted into clinical practice at this stage as little is known about its mechanism of action on modulating the immunity during cancer treatment. The proposed mechanisms by which bacteria act as anti-cancer agents have been studied and proposed to be either through enhancing human immunity, activating inflammasome pathways, CD4, CD25 and CD8 anti-tumor effectors T cell responses, TNF-a innate immune system in bacteria-based tumor

necrosis, through released substances (such as bacteriocins, biosurfactants, phenazine 1,6-di-carboxylic

acid). They also act as a carrier for cancer therapeutic agents and bacteria-based microrobot (Bacteriobot)

[8].

The intestinal microbiota play a relevant role in disorders of the nervous system. The microbiota-gut-

brain axis may represent a new target in the prevention and treatment of neuropsychiatric disorders.

Analyses of the available research results have shown that selected bacteria affect the gut-brain axis in

healthy people and people with selected diseases i.e., Alzheimer's disease, Parkinson's disease,

depression, and autism spectrum disorders and hence acquired the term "Psychobiotics" [9].

In conclusion, bacteriotherapy is an old-modern concept in the field of therapeutics showing promising

findings. Bacteriotherapy is a rich field for conducting clinical research and investigations taking into

consideration its potential adverse effects in the future work.

Keywords: Probiotics, fecal microbiota transplantation, dysbiosis, microbiota

2

REFERENCES

- [1] Altveş S, Yildiz HK, Vural HC. Interaction of the microbiota with the human body in health and diseases. Biosci Microbiota Food Health. 2020;39(2):23-32. [CrossRef].
- [2] Martinez JE, Kahana DD, Ghuman S, Wilson HP, Wilson J, Kim J, Lagishetty V, Jacobs P, Sinha-Hikim P, Friedman C. Unhealthy lifestyle and gut dysbiosis: A better understanding of the effects of poor diet and nicotine on the intestinal microbiome. Frontiers Endocrinol. 2021;12,667066. [CrossRef].
- [3] Yoshimatsu Y, Mikami Y, Kanai T. Bacteriotherapy for inflammatory bowel disease. Inflamm Regen. 2021;13,41(1):3. [CrossRef].
- [4] Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37(1):42–47.
- [5] You D, Johnson M, Duplessis C, Speziale A. Successful use of fecal bacteriotherapy in severe Crohn's colitis and refractory *Clostridium difficile* infection: 845. AJG Am J Gastroenterol. 2011;106:S315.
- [6] Zhang Z, Mocanu V, Cai C, Dang J, Slater L, Deehan EC, Walter J, Madsen KL. Impact of fecal microbiota transplantation on obesity and metabolic syndrome-A systematic review. Nutrients. 2019;11(10):2291. [CrossRef].
- [7] Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018; 33(4):570-580. [CrossRef].
- [8] Baindara P, Mandal SM. Bacteria and bacterial anticancer agents as a promising alternative for cancer therapeutics. Biochimie. 2020,177;164–189. [CrossRef].
- [9] Del Toro-Barbosa M, Hurtado-Romero A, Garcia-Amezquita LE, García-Cayuela T. Psychobiotics: Mechanisms of action, evaluation methods and effectiveness in applications with food products. Nutrients. 2020;12(12):3896. [CrossRef].